July 07, 2015
Below are current clinical trials.11 studies in Parkinson's disease
(open studies only).
Filter this list of studies by location, status and more.
The purpose of this study is to evaluate the safety and effectiveness of Boston Scientific's Vercise Deep Brain Stimulation (DBS) system in the treatment of patients with with advanced, levodopa-responsive bilateral Parkinson's disease (PD) which is not adequately controlled with medication.
The purpose of this study is ongoing longitudinal clinicopathologic studies of normal aging and Parkinson's Disease subjects. Specific projects of motor, non-motor and peripheral manifestations of Parkinson’s disease (PD) as possible early markers of PD onset in otherwise asymptomatic elderly people. Cognitive and non-cognitive markers of eventual dementia onset in previously non-demented persons with PD.
Jacksonville, Fla., Rochester, Minn.
This study is investigating the usefulness of using functional magnetic resonance imaging (fMRI) to monitor brain activation during deep brain stimulation for Parkinson's Disease. The study may determine the relationship between patterns of brain activation and therapeutic outcome and/or side effects.
The purpose of this study is to compare treadmill walking and over ground walking gait characteristics in people diagnosed with Parkinson’s disease.
The purpose of this study is to learn more about Lewy Body disease and a skin condition called Bullous Pemphigoid.
This study will determine the validity of predictive and surrogate biomarkers for the detection of Parkinson's disease and Parkinson's disease cognitive decline.
The potential role of Small bowel bacterial overgrowth (SBBO) in weight loss occurring in patients with PD has not previously been examined. Our hypothesis is that SBBO is an important contributor to the development of weight loss in individuals with Parkinson's disease. The investigators propose to 1) examine the role of SBBO in weight loss occurring in patients with PD and 2) determine the response to its treatment with a poorly absorbed antibiotic. The investigators propose to perform a prospective, observational case-control study with an open-label therapeutic component. Cases will be defined as those PD patients who've experienced significant weight loss while Controls will be defined as those PD patients who have not experienced significant weight loss.
The goal of this study is to establish and maintain a neurology disease biospecimen bank containing samples of blood and/or cerebral spinal fluid from patients with symptoms of cognitive decline as well as patients with symptoms of Parkinson’s disease.
This study is designed to evaluate the high-frequency range deep brain oscillations (HFO) as pathologic markers in patients undergoing deep brain stimulation for epilepsy or Parkinson disease. Newly developed technology allows for the chronic recording of these brain signals at the same time as clinical stimulation is occuring. We will learn both whether these HFO correlate with disease activity and whether the HFO change in response to ongoing stimulation (potentially giving insight into the underlying mechanism of action of DBS). Study participants will undergo DBS in the same way as is usually done but will receive this newer battery with ability to record brain signals.
In this study, the investigators will monitor extracellular neurotransmitter levels using a probe that is able to perform real time electrochemical detection during deep brain stimulation surgery. The overall question this study is designed to answer is: Are there neurotransmitters released during deep brain stimulation?
- Longo DL, et al. Parkinson's disease and other movement disorders. In: Harrison's Principles of Internal Medicine. 18th ed. New York, N.Y.: The McGraw-Hill Companies; 2012. http://accessmedicine.com. Accessed April 6, 2015.
- Parkinson's disease: Hope through research. National Institute of Neurological Disorders and Stroke. http://www.ninds.nih.gov/disorders/parkinsons_disease/detail_parkinsons_disease.htm. Accessed April 6. 2015.
- Ferri FF. Parkinson's disease. In: Ferri's Clinical Advisor 2015: 5 Books in 1. Philadelphia, Pa.: Mosby Elsevier; 2015. https://www.clinicalkey.com. Accessed April 6, 2015.
- Chou KL. Diagnosis of Parkinson disease. http://www.uptodate.com/home. Accessed April 6. 2015.
- Tarsy D. Pharmacologic treatment of Parkinson disease. http://www.uptodate.com/home. Accessed April 6. 2015.
- Adler CH, et al. Submandibular gland needle biopsy for the diagnosis of Parkinson disease. Neurology. 2014;82:858.
- Bousquet M, et al. Impact of omega-3 fatty acids in Parkinson's disease. Ageing Research Reviews. 2011;10:453.
- Parkinson's disease: Fitness counts. National Parkinson Foundation. http://www.parkinson.org/Search-Pages/Search.aspx?pKeywords=fitness. Accessed April 9, 2015.
- Parkinson's disease. Natural Medicines Comprehensive Database. http://www.naturaldatabase.com. Accessed April 6, 2015.
- Tarsy D. Nonpharmacologic management of Parkinson disease. http://www.uptodate.com/home/. Accessed April 6, 2015.
- Complementary therapies and Parkinson's. Parkinson's Disease Society of the United Kingdom. http://www.parkinsons.org.uk/content/complementary-therapies-and-parkinsons-booklet. Accessed April 9, 2015.
- Jankovic J. Etiology and pathogenesis of Parkinson disease. http://www.uptodate.com/home. Accessed April 6, 2015.
- Riggs EA. Decision Support System. Mayo Clinic, Rochester, Minn. April 16, 2015.
- Abbvie announces U.S. approval of duopa (carbidopa and levodopa) enteral suspension for the treatment of motor fluctuations in patients with advanced Parkinson's disease. http://abbvie.mediaroom.com/2015-01-12-AbbVie-Announces-U-S-FDA-Approval-of-DUOPA-carbidopa-and-levodopa-Enteral-Suspension-for-the-Treatment-of-Motor-Fluctuations-in-Patients-with-Advanced-Parkinsons-Disease. Accessed April 20, 2015.
- Bower JH (expert opinion). Mayo Clinic, Rochester, Minn. April 20, 2015.